Le Lézard
Classified in: Health
Subject: FDA

Targovax receives Fast Track designation for ONCOS-102 in melanoma

OSLO, Norway, June 22, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast Track designation in PD-1-refractory advanced melanoma from the US FDA.  

The US FDA has granted Fast Track designation to ONCOS-102 based on the current pre-clinical and clinical data package, including mechanistic evidence showing an association between ONCOS-102-induced immune activation and tumor responses. Receiving this designation is an endorsement by the US FDA of the strength and importance of the ONCOS-102 data package in PD-1-refractory advanced melanoma. This Fast Track approval comes in addition to ONCOS-102´s existing Fast Track designation in malignant pleural mesothelioma.

The FDA Fast Track designation is awarded to therapies with potential to address unmet medical needs in serious medical conditions and allows for more frequent interactions with the FDA to expedite clinical development, as well as the regulatory review processes. Fast Track products have high likelihood of receiving Priority Review for a future Biologics License Application (BLA) and may be allowed to submit parts of the application for rolling review to shorten the approval timeline.

Dr. Ingunn Munch Lindvig, VP Regulatory Affairs of Targovax said "Securing yet another Fast Track designation is a strong endorsement of the potential for ONCOS-102 to benefit a patient population with high unmet medical need. Fast Track simplifies and expedites the regulatory interactions and review process, and further supports the rationale for initiating a Phase 2 trial to target accelerated approval for ONCOS-102 in anti-PD1 refractory melanoma."


Oystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com 

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com 

Media enquires:
Andreas Tinglum
- Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777

This information was brought to you by Cision http://news.cision.com


SOURCE Targovax

These press releases may also interest you

at 07:00
EpiEndo Pharmaceuticals (www.epiendo.com) is pleased to announce that it is the recipient of this year's Rising Star Award at the Swedish American Life Sciences Summit (SALSS). EpiEndo is a privately held biopharmaceutical company focused on a novel...

at 07:00
Bristol Myers Squibb today announced that it has changed the timing of its previously announced earnings conference call. The Company will now host a conference call to discuss results for the third quarter of 2021 on Wednesday, October 27, 2021 at...

at 06:57
Therapon Skin Health, the makers of the medical-grade skin care line, Theraderm Clinical Skin Care, announces the re-launch of one of its foundational products, Theraderm Cool Skin. Previously known as Instant Cool Skin under the Therapon brand, this...

at 06:50
Merck , known as MSD outside the United States and Canada, today announced positive top-line results from two pivotal Phase 3 trials of the investigational, once-daily oral fixed dose combination pill of doravirine/islatravir (DOR/ISL) in adults with...

at 06:47
Announcement by leading chemicals company in line with its 'Chemistry for Better Living' commitment, providing clear pathway to improving people's quality of life through transformation to low carbon business Ambitious plan will use Three-Pillar Low...

at 06:45
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. ("Bausch Health"), and Clearside Biomedical, Inc. ("Clearside"), a biopharmaceutical company revolutionizing the...

News published on 22 june 2021 at 01:09 and distributed by: